Air Liquide :Acquisition of NordicInfu Care, a major player in home
infusion in the Nordic countries
PARIS -- March 5, 2013
Air Liquide (Paris:AI) continues the development of its home healthcare
activity in Europe with the acquisition of NordicInfu Care, a major player in
home infusion therapy for patients with chronic diseases in the Nordic
Founded in 2002, NordicInfu Care takes care of 4,600 patients in Sweden,
Norway, Denmark and Finland. In 2012, the company generated revenue of
approximately € 22million (SEK 185 million).
NordicInfu Care is recognized for its expertise in the treatment of chronic
diseases such as Parkinson's disease, diabetes, and pulmonary hypertension, by
subcutaneous infusion at home.
Its integrated range of solutions, which includes the medication as well as
the medical equipment, allows patients to be treated at home rather than go to
hospital, thereby giving them greater autonomy.
Air Liquide favours continuity in the company's management, which is presided
by Mats Bergryd, relying on the expertise and the commitment of its teams.
This acquisition also marks a new geographical development for Air Liquide's
home healthcare activities, which until now had little presence in these
Northern European countries.
Pascal Vinet, Vice President, Healthcare Global Operations and member of the
Group’s Executive Committee, commented: "We are delighted to welcome these new
employees to the Group.
With this acquisition, AirLiquide is taking another step in home infusion
treatment for patients suffering from chronic diseases in Europe. Health is
one of the Group's growth drivers."
Air Liquide’s Healthcare Business line
Air Liquide's Healthcare World Business Line supplies medical gases, home
healthcare services, hygiene products, medical equipment and specialty
In 2012, it served over 7,500hospitals and 1 millionpatients at home
throughout the world.
The Group’s Healthcare business line also reached € 2,482million in revenues
in 2012, with 10,000employees.
Air Liquide, European leader and 3^rd worldwide in home healthcare, provides
home healthcare services in compliance with medical prescription for patients
suffering from chronic diseases such as COPD (Chronic Obstructive Pulmonary
Disease), sleep apnea and diabetes. These home healthcare services are being
developed in addition to hospital care, enabling patients to enjoy better
quality of life and local authorities to reduce costs.
Home Healthcare represents 43% of AirLiquide’s total 2012 Healthcare revenue.
Air Liquide in the Nordic countries
Air Liquide is present in Denmark, Norway, Finland and Sweden with more than
500 employees. The Group operates a total of 50 sites in these countries, and
serves more than 50,000 customers in most industries and healthcare.
Air Liquide is the world leader in gases for industry, health and the
environment, and is present in 80countries with close to 50,000employees.
Oxygen, nitrogen, hydrogen and rare gases have been at the core of Air
Liquide’s activities since its creation in 1902. Using these molecules, Air
Liquide continuously reinvents its business, anticipating the needs of current
and future markets. The Group innovates for the good of society while
delivering growth and consistent performance.
Innovative technologies that curb polluting emissions, lower industry’s energy
use, recover and reuse natural resources or develop the energies of tomorrow,
such as hydrogen, biofuels or photovoltaic energy… Oxygen for hospitals, home
healthcare, fighting nosocomial infections… Air Liquide combines many products
and technologies to develop valuable applications and services not only for
its customers but also for society.
A partner for the long term, Air Liquide relies on employee commitment,
customer trust and shareholder support to pursue its vision of sustainable,
competitive growth. The diversity of Air Liquide’s teams, businesses, markets
and geographic presence provides a solid and sustainable base for its
development and strengthens its ability to push back its own limits, conquer
new territories and build its future.
Air Liquide explores the best that air can offer to preserve life, staying
true to its Corporate Social Responsibility and sustainable development
approach. In 2012, the Group’s revenues amounted to €15.3billion of which
82% were generated outside France. AirLiquide is listed on the Paris Euronext
stock exchange (compartment A) and is a member of the CAC 40 and Dow Jones
Euro Stoxx 50 indexes.
Follow us on Twitter @AirLiquideGroup
+ 33 (0)1 40 62 51 31
+ 33 (0)1 40 62 59 62
+33 (0) 1 40 62 57 37
+33 (0) 1 40 62 57 18
Air Liquide Healthcare Communications
+ 33 (0)1 49 69 46 46
Press spacebar to pause and continue. Press esc to stop.